

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) An isolated antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:48, wherein said antibody immunospecifically binds to a respiratory syncytial virus (RSV) F protein.
2. (Canceled)
3. (Currently Amended) An isolated antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:20, wherein said antibody immunospecifically binds to a RSV F protein.
4. (Canceled)
5. (Previously Presented) The antibody of claim 3 further comprising a VH domain having an amino acid sequence of SEQ ID NO:48.
- 6.-178. (Canceled)
179. (Previously Presented) An isolated antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a VH CDR of the antibody A4B4, wherein said antibody immunospecifically binds to a RSV F protein.
180. (Previously Presented) An isolated antibody comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10, wherein said antibody immunospecifically binds to a RSV F protein.
181. (Previously Presented) An isolated antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:18, wherein said antibody immunospecifically binds to a RSV F protein.
182. (Previously Presented) An isolated antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.

183. (Previously Presented) An isolated antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:21, wherein said antibody immunospecifically binds to a RSV F protein.
184. (Previously Presented) An isolated antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
185. (Canceled)
186. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
187. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
188. (Canceled)
189. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
- 190.-191. (Canceled)
192. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
193. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
194. (Canceled)
195. (Previously Presented) The antibody of claim 184, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 196.-200. (Canceled)

201. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22 and a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 202.-203. (Canceled)
204. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
205. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
206. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
207. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
208. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
209. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
210. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
211. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

212. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 213.-221. (Canceled)
222. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
223. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
224. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
225. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
226. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
227. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 228.-230. (Canceled)
231. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.
232. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

233. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 234-240. (Canceled)
241. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
242. (Previously Presented) The antibody of claim 223, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
243. (Canceled).
244. (Previously Presented) The antibody of claim 225, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
245. (Previously Presented) The antibody of claim 226, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.
- 246-249. (Canceled)
250. (Previously Presented) The antibody of claim 231, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.
- 251-279. (Canceled)
280. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a monoclonal antibody.
281. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a human antibody.
282. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a humanized antibody.
283. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a Fab fragment.

284. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a therapeutic or drug moiety.
285. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a detectable substance.
286. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184 and a pharmaceutically acceptable carrier.
287. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184 and instructions for use, in one or more containers.
288. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
289. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
290. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
291. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
292. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
293. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

294. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
295. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.
296. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
297. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
298. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
299. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.
- 300.-302. (Canceled)
303. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
304. (Canceled)
305. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

306. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
307. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
308. (Currently Amended) An isolated antibody comprising a CDR having an amino acid sequence of a VL CDR of the antibody ~~P12F4~~P12F2.